Intensive care medicine

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Fast Track, Therapy, HCP, Chronic liver disease, David Berry (inventor), Recurrence, Clostridioides difficile infection, Infection, Research, Fast track (FDA), Education, FDA, Term loan, Variometer, Growth, Use, Retirement, ID, Sale, CDI, Immunodeficiency, Oaktree Capital Management, Risk, Commercial, Graft-versus-host disease, Intensive care medicine, Medicare, Spore, Patient, Medicare Part D, Acceleration, Gastroenterology, Clostridioides, Limitation, AMR, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
  • From launch through year-end 2023, there were 2,833 completed prescription enrollment forms received for VOWST, of those 2,015 resulted in new patient starts by year-end 2023.
  • Strong adoption of VOWST since commercial launch in June 2023 with broad utilization, continued quarter over quarter growth, and significant progress achieving patient access.
  • General and administrative expenses for the fourth quarter of 2023 were $17.2 million, compared with $22.4 million for the same period in 2022.

EMVision Sets Sight on US With US$10M Keysight Investment

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Technology, Professional Services, Other Health, Health, General Health, Other Technology, Medical Devices, Artificial Intelligence, Hardware, Finance, Acquisition, OEM, Multimedia, FDA, Quality of life, Growth, Sale, Stroke, Regulatory affairs, Joint Medical Service (Germany), Intensive care medicine, Patient, Google Images, VNA, Head, Artificial intelligence, MRI, Partnership, Medical imaging

EMVision, an Australian medical device company focused on developing innovative portable brain imaging technology, has announced a US$10 million (~A$15.28m) strategic investment from Keysight Technologies, a global leader in test and measurement technology.

Key Points: 
  • EMVision, an Australian medical device company focused on developing innovative portable brain imaging technology, has announced a US$10 million (~A$15.28m) strategic investment from Keysight Technologies, a global leader in test and measurement technology.
  • (Photo: Business Wire)
    The investment provides EMVision with a fully funded commercial runway for its emu™ device.
  • It accelerates clinical trials, generating essential data supporting the upcoming regulatory approval pathway and adoption in the world’s largest healthcare market.
  • Under the agreement, Keysight will be issued 7,454,231 new ordinary shares in EMVision at A$2.05 per share to acquire an 8.73% shareholding in EMVision.

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market

Retrieved on: 
Thursday, February 29, 2024
VAPO, Intensive care medicine, Social media, Hospital, Compressed air, USD, Ageing, Periodic breathing, HVT, Vapotherm, Health, Patient, Optimism, OTCQX, COPD, Pharmaceutical industry

With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."

Key Points: 
  • With the approval and subsequent launch of HVT 2.0 in Brazil, we look forward to establishing ourselves as a frontline solution in Latin America."
  • These features facilitate optimal patient care in the most advanced hospitals as well as resource constrained environments.
  • With the approval of the new system in Brazil, Vapotherm is launching a new Portuguese website and social media campaign.
  • The Company attended in the XXVIII Brazilian Congress of Intensive Care Medicine, the largest event of its kind in Latin America, to collaborate with approximately three thousand clinicians.

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
Viral, Internet, Call, MAMC, Blood, Interest, Exosome, Marketing, Maulana Azad Medical College, Metastasis, Organ transplantation, Ethics, Interim, Intensive care medicine, COVID-19, Consolidated, DCGI, Virus, Patient, Clinical trial, Infection, Plasma, Insurance, Research, Travel, Cancer, Pharmaceutical industry

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. 

Key Points: 
  • ET
    SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.
  • "While our research and development team has started to quantify our internal data, the results, to date, are inconclusive.
  • Financial Results for the Third Quarter Ended December 31, 2023
    As of December 31, 2023, Aethlon Medical had a cash balance of approximately $8.0 million.
  • ET to review its financial results for its fiscal third quarter ended December 31, 2023 and recent corporate developments.

PCA 500™-- the world's most efficient and versatile 12-lead ECG, receives FDA clearance for use in acute care

Retrieved on: 
Tuesday, February 13, 2024
Chest pain, Acquisition, Bangladesh Technical Education Board, Hospital, PCA, NIH, FDA, Digital, ECG, Ambulance, Intensive care medicine, EKG, School, Patient, Diagnosis, Medical imaging

PCA 500 was first 510(k) cleared in 2018 for professional and personal use by adults in non-acute care settings, including patient's homes.

Key Points: 
  • PCA 500 was first 510(k) cleared in 2018 for professional and personal use by adults in non-acute care settings, including patient's homes.
  • In 2022, QT Medical received 510(k) clearance of PCA 500 use in infants, children and adolescents.
  • The new FDA clearance expands PCA 500's indication for use to all healthcare settings, including: hospitals, intensive care units, emergency rooms and ambulances.
  • With the FDA clearance for use in acute care, such as ambulances and emergency rooms, PCA 500 brings significant values to where efficiency and accuracy are needed the most."

HemoSonics' Quantra® Hemostasis System Named as a Finalist in the World Renowned 2024 Edison Awards

Retrieved on: 
Tuesday, February 13, 2024
Thomas Edison, Engineering, Cartridge, Hospital, Boston Scientific, Caregiver, Elasticity, Biotechnology, Education, Marketing, FDA, Gold, Health, Intensive care medicine, Edison Awards, GE HealthCare, Medtech, Patient, Operating, Apple, Lockheed, Science, Silver, Pharmaceutical industry

DURHAM, N.C., Feb. 13, 2024 /PRNewswire/ -- HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced that its Quantra Hemostasis System with QPlus® and QStat® Cartridges has been named a finalist in the 2024 Edison™ Awards. The company was honored in the health, medical, and biotechnology category for its Quantra Hemostasis System. The Quantra System with QPlus and QStat Cartridges provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.

Key Points: 
  • The company was honored in the health, medical, and biotechnology category for its Quantra Hemostasis System.
  • The Quantra System with QPlus and QStat Cartridges provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.
  • Named after the American inventor Thomas Alva Edison, the Edison Awards recognize the world's most innovative products and business leaders, including Steve Jobs, Jony Ive, Gwynne Shotwell, Ginni Rometty, Apple, Nest, 3M, Lockheed Martin and many more.
  • The Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges.

New data shows aggression and violence are issues for all hospital staff - 60% of reported threats happen outside the emergency department

Retrieved on: 
Tuesday, February 13, 2024
Workplace violence, PALO, Hospital, Intensive care unit, Violence, Physician, Human, Holiday, Safety, Intensive care medicine, Anesthesia, Nursing, Patient, COVID, Bureau of Labor Statistics, Workforce, Research

PALO ALTO, Calif., Feb. 13, 2024 /PRNewswire/ -- Canopy, the creator of an industry-leading safety solution to protect hospital staff from workplace aggression and violence, today shared new 2023 data that shows the threat of violence is pervasive across hospital grounds. It impacted more than 10% of all hospital staff last year in every role – from nurses to physicians, to cafeteria and gift shop workers – and in every area of the hospital campus.

Key Points: 
  • It impacted more than 10% of all hospital staff last year in every role – from nurses to physicians, to cafeteria and gift shop workers – and in every area of the hospital campus.
  • Last year, hospital staff triggered 22,000 alerts requesting immediate help with an emerging threat or active violence among 200,000 employees equipped with duress buttons created by Canopy.
  • "Frontline healthcare workers want to save lives and care for patients – workplace aggression isn't part of the job they sign up for.
  • Surprisingly, alerts were less frequent during weekends and holidays, despite being some of the busiest, and often understaffed, times for hospital emergency departments.

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

Retrieved on: 
Monday, February 12, 2024
Pseudomonas aeruginosa, Infection, ICU, Escherichia coli, Catheter, Acinetobacter baumannii, FDA, Food, Carbapenem, Bloodstream infections, Risk, Intensive care medicine, Bacteria, World Health Organization, Patient, Septic shock, S. aureus, Mortality

LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to the expansive panel.

Key Points: 
  • LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to the expansive panel.
  • “We are thrilled to receive the FDA 510(k) clearance for the expanded T2Bacteria Panel, to include the detection of A. baumannii, as we believe it will lead to increased adoption of our proprietary direct-from-blood platform,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • The FDA-cleared T2Bacteria Panel now detects E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, E. coli, and A. baumannii.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.

Philips Sounds transform the sound of care, reducing patient monitoring alarm noise by up to 66%

Retrieved on: 
Tuesday, February 6, 2024
Canadian Medical Association, Anxiety, ICU, PHG, Attention, Noise, Research, Intensive care medicine, Caregiver, Environment, Patient, FDA, Fatigue, Quality of life, Health, AEX, Hospital, Nursing

In the average ICU, patient monitors account for up to 82% of alarm tones [1] with up to 350 alarms per patient every day [2].

Key Points: 
  • In the average ICU, patient monitors account for up to 82% of alarm tones [1] with up to 350 alarms per patient every day [2].
  • To help drive alarm management strategies toward a more peaceful, healing environment for patients and caregivers alike, Philips has applied a fresh perspective to acute patient monitor alarm sounds by collaborating with clinicians and world-leading sound experts.
  • Philips’ new patient monitoring sounds have been proven to reduce alarm noise by up to 66% [5].
  • The Philips 2021 interval for cyan alarms is every 2 seconds compared to every 6 seconds with traditional sounds.